Literature DB >> 19139817

Differential gene expression triggered by highly cytotoxic alpha-emitter-immunoconjugates in gastric cancer cells.

Christof Seidl1, Matthias Port, Christos Apostolidis, Frank Bruchertseifer, Markus Schwaiger, Reingard Senekowitsch-Schmidtke, Michael Abend.   

Abstract

Immunoconjugates composed of the alpha-emitter (213)Bi and the monoclonal antibody d9MAb specifically target HSC45-M2 gastric cancer cells expressing mutant d9-E-cadherin. These conjugates efficiently killed tumor cells in a nude mouse peritoneal carcinomatosis model. To elucidate the molecular responses of HSC45-M2 cells to alpha-emitter irradiation, whole genome gene expression profiling was performed. For that purpose HSC45-M2 cells were incubated with lethal doses of (213)Bi-d9MAb. RNA was isolated at 6, 24 and 48 h after irradiation, transcribed into cDNA and hybridized to whole genome microarrays. Results of microarray analysis were validated using RTQ-PCR showing correspondence of approximately 90%. Following incubation with (213)Bi-d9MAb, 682-1125 genes showed upregulation and 666-1278 genes showed downregulation at one time point, each. Eight genes appeared upregulated and 12 genes downregulated throughout. Molecular functions and biological processes of differentially expressed genes were categorized according to the PANTHER database. Following (213)Bi-d9MAb irradiation also a time-dependent shift in terms of overrepresentation of biological processes was observed. Among the genes showing continuous upregulation, COL4A2, NEDD9 and C3 have not been associated with the cellular response to high LET radiation so far. The same holds true for WWP2, RFX3, HIST4H4 and JADE1 that showed continuous downregulation. According to PANTHER, three of the consistently upregulated (ITM2C, FLJ11000, MSMB) and downregulated (HCG9, GAS2L3, FLJ21439) genes, respectively, have not been associated with any biological process or molecular function so far. Thus, these findings revealed interesting new targets for selective elimination of tumor cells and new insights regarding response of tumor cells to alpha-emitter exposure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139817     DOI: 10.1007/s10637-008-9214-4

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  54 in total

1.  Wwp2-mediated ubiquitination of the RNA polymerase II large subunit in mouse embryonic pluripotent stem cells.

Authors:  Hui Li; Zhihong Zhang; Beibei Wang; Junmei Zhang; Yingming Zhao; Ying Jin
Journal:  Mol Cell Biol       Date:  2007-05-25       Impact factor: 4.272

Review 2.  Signals from within: the DNA-damage-induced NF-kappaB response.

Authors:  S Janssens; J Tschopp
Journal:  Cell Death Differ       Date:  2006-05       Impact factor: 15.828

Review 3.  Current status and perspectives in alpha radioimmunotherapy.

Authors:  M Chérel; F Davodeau; F Kraeber-Bodéré; J F Chatal
Journal:  Q J Nucl Med Mol Imaging       Date:  2006-12       Impact factor: 2.346

4.  Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death.

Authors:  Christof Seidl; Hedwig Schröck; Sabine Seidenschwang; Roswitha Beck; Ernst Schmid; Michael Abend; Karl-Friedrich Becker; Christos Apostolidis; Tuomo K Nikula; Elisabeth Kremmer; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

Review 5.  Apoptotic and necrotic cell death induced by death domain receptors.

Authors:  G Denecker; D Vercammen; W Declercq; P Vandenabeele
Journal:  Cell Mol Life Sci       Date:  2001-03       Impact factor: 9.261

6.  Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.

Authors:  Claudia Friesen; Gerhard Glatting; Bernd Koop; Klaus Schwarz; Alfred Morgenstern; Christos Apostolidis; Klaus-Michael Debatin; Sven N Reske
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

7.  Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model.

Authors:  Emma Y Song; Chang F Qu; Syed M A Rizvi; Chand Raja; Julia Beretov; Alfred Morgenstern; Christos Apostolidis; Frank Bruchertseifer; Alan Perkins; Barry J Allen
Journal:  Cancer Biol Ther       Date:  2007-10-08       Impact factor: 4.742

Review 8.  The spindle checkpoint, aneuploidy, and cancer.

Authors:  Rajnish Bharadwaj; Hongtao Yu
Journal:  Oncogene       Date:  2004-03-15       Impact factor: 9.867

9.  A radiation-induced gene signature distinguishes post-Chernobyl from sporadic papillary thyroid cancers.

Authors:  M Port; C Boltze; Y Wang; B Röper; V Meineke; M Abend
Journal:  Radiat Res       Date:  2007-12       Impact factor: 2.841

10.  Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.

Authors:  H Matthias Buchhorn; Christof Seidl; Roswitha Beck; Dieter Saur; Christos Apostolidis; Alfred Morgenstern; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-06       Impact factor: 10.057

View more
  13 in total

1.  177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.

Authors:  Christof Seidl; Christine Zöckler; Roswitha Beck; Leticia Quintanilla-Martinez; Frank Bruchertseifer; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-12       Impact factor: 9.236

Review 2.  Molecular pathways: targeted α-particle radiation therapy.

Authors:  Kwamena E Baidoo; Kwon Yong; Martin W Brechbiel
Journal:  Clin Cancer Res       Date:  2012-12-10       Impact factor: 12.531

3.  Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: a feasibility study.

Authors:  Stephane Supiot; Wilfried Gouraud; Loïc Campion; Pascal Jezéquel; Bruno Buecher; Josiane Charrier; Marie-Francoise Heymann; Marc-Andre Mahé; Emmanuel Rio; Michel Chérel
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

Review 4.  CAS proteins in normal and pathological cell growth control.

Authors:  Nadezhda Tikhmyanova; Joy L Little; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2009-11-25       Impact factor: 9.261

5.  Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.

Authors:  Diane E Milenic; Kwamena E Baidoo; Young-Seung Kim; Rachel Barkley; Martin W Brechbiel
Journal:  Dalton Trans       Date:  2017-10-31       Impact factor: 4.390

6.  Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

7.  Genomic profiling of a human leukemic monocytic cell-line (THP-1) exposed to alpha particle radiation.

Authors:  Vinita Chauhan; Matthew Howland
Journal:  ScientificWorldJournal       Date:  2012-10-11

8.  Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells.

Authors:  Mareike Roscher; Inis Hormann; Oliver Leib; Sebastian Marx; Josue Moreno; Erich Miltner; Claudia Friesen
Journal:  Oncotarget       Date:  2013-02

9.  Gene expression signature in mouse thyroid tissue after (131)I and (211)At exposure.

Authors:  Nils Rudqvist; Johan Spetz; Emil Schüler; Britta Langen; Toshima Z Parris; Khalil Helou; Eva Forssell-Aronsson
Journal:  EJNMMI Res       Date:  2015-10-22       Impact factor: 3.138

10.  Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.

Authors:  Kwon Joong Yong; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.